Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
Study sponsor: LB Pharmaceuticals Inc. · LBRX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-02Estimated
Enrollment · participants320Estimated
Source updated2026-07-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.